Home
RCUS
RCUS News

Latest Arcus Biosciences Inc. (RCUS) News on July 5, 2025

Argus Research

11 days ago

RCUS: What does Argus have to say about RCUS?

Business Wire

11 days ago

Arcus Biosciences Announces New Employment Inducement Grants

Argus Research

25 days ago

RCUS: Rating decreased to a SELL

Business Wire

25 days ago

Arcus Biosciences Announces New Employment Inducement Grants

Business Wire

a month ago

Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response

Business Wire

a month ago

Arcus Biosciences Announces New Employment Inducement Grants

Argus Research

a month ago

RCUS: What does Argus have to say about RCUS?

Argus Research

2 months ago

RCUS: What does Argus have to say about RCUS?

MT Newswires

2 months ago

Morgan Stanley Lowers Price Target on Arcus Biosciences to $22 From $24, Keeps Overweight Rating

Arcus Biosciences First Quarter 2025 Earnings: Misses Expectations

Simply Wall St.

2 months ago

Arcus Biosciences First Quarter 2025 Earnings: Misses Expectations

Thomson Reuters StreetEvents

2 months ago

Q1 2025 Arcus Biosciences Inc Earnings Call

Arcus Biosciences Inc (RCUS) Q1 2025 Earnings Call Highlights: Strategic Focus and Financial ...

GuruFocus.com

2 months ago

Arcus Biosciences Inc (RCUS) Q1 2025 Earnings Call Highlights: Strategic Focus and Financial ...

Argus Research

2 months ago

RCUS: What does Argus have to say about RCUS?

Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Lags Revenue Estimates

Zacks

2 months ago

Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Lags Revenue Estimates

Business Wire

2 months ago

Arcus Biosciences Reports First-Quarter 2025 Financial Results and Provides a Pipeline Update

Earnings To Watch: Arcus Biosciences Inc (RCUS) Reports Q1 2025 Result

GuruFocus.com

2 months ago

Earnings To Watch: Arcus Biosciences Inc (RCUS) Reports Q1 2025 Result

Business Wire

2 months ago

Arcus Biosciences Announces New Employment Inducement Grants

Business Wire

2 months ago

Arcus Biosciences to Present First Combination Data for HIF-2a Inhibitor Casdatifan Plus Cabozantinib in an Oral Presentation at the 2025 ASCO Annual Meeting

Argus Research

2 months ago

RCUS: What does Argus have to say about RCUS?

Business Wire

2 months ago

Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2025 Financial Results and Pipeline Update

Argus Research

3 months ago

RCUS: Raising target price to $8.00

Business Wire

3 months ago

Arcus Biosciences Announces New Employment Inducement Grants

Argus Research

3 months ago

RCUS: Lowering target price to $7.00

Argus Research

3 months ago

RCUS: Rating increased to a HOLD

Arcus Biosciences, Inc.'s (NYSE:RCUS) latest 8.6% decline adds to one-year losses, institutional investors may consider drastic measures

Simply Wall St.

3 months ago

Arcus Biosciences, Inc.'s (NYSE:RCUS) latest 8.6% decline adds to one-year losses, institutional investors may consider drastic measures

Argus Research

3 months ago

RCUS: What does Argus have to say about RCUS?

Business Wire

3 months ago

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (RCUS): Among Top Insider Purchases Last Month

Insider Monkey

4 months ago

Arcus Biosciences, Inc. (RCUS): Among Top Insider Purchases Last Month

Argus Research

4 months ago

RCUS: What does Argus have to say about RCUS?

Arcus Biosciences (RCUS): Among Stocks With At Least $10 Million In Insider Spending Recently

Insider Monkey

4 months ago

Arcus Biosciences (RCUS): Among Stocks With At Least $10 Million In Insider Spending Recently

Insider Buying: Arcus Biosciences Co-Founder Bought US$201k Of Shares

Simply Wall St.

4 months ago

Insider Buying: Arcus Biosciences Co-Founder Bought US$201k Of Shares

Arcus Biosciences, Inc. (NYSE:RCUS) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Simply Wall St.

4 months ago

Arcus Biosciences, Inc. (NYSE:RCUS) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Business Wire

4 months ago

Arcus Biosciences to Participate in Two Upcoming Investor Conferences

MT Newswires

4 months ago

HC Wainwright Upgrades Arcus Biosciences to Buy From Neutral, Adjusts Price Target to $24 From $18

Argus Research

4 months ago

RCUS: Rating decreased to a SELL

Arcus Biosciences, Inc. (RCUS) Reports Q4 Loss, Tops Revenue Estimates

Zacks

4 months ago

Arcus Biosciences, Inc. (RCUS) Reports Q4 Loss, Tops Revenue Estimates

Business Wire

4 months ago

Arcus Biosciences Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides a Pipeline Update

Arcus Biosciences Inc (RCUS) Q4 2024: Everything You Need to Know Ahead of Earnings

GuruFocus.com

4 months ago

Arcus Biosciences Inc (RCUS) Q4 2024: Everything You Need to Know Ahead of Earnings

Business Wire

4 months ago

Arcus Biosciences Announces New Employment Inducement Grants

These Analysts Just Made A Decent Downgrade To Their Arcus Biosciences, Inc. (NYSE:RCUS) EPS Forecasts

Simply Wall St.

5 months ago

These Analysts Just Made A Decent Downgrade To Their Arcus Biosciences, Inc. (NYSE:RCUS) EPS Forecasts

Argus Research

5 months ago

RCUS: Lowering target price to $12.00

MT Newswires

5 months ago

Wedbush Cuts Arcus Biosciences' Price Target to $33 From $36, Keeps Outperform Rating

Arcus says new data demonstrated ‘best-in-class potential’ for casdatifan

TipRanks

5 months ago

Arcus says new data demonstrated ‘best-in-class potential’ for casdatifan

MT Newswires

5 months ago

Arcus Biosciences Prices $150 Million Share Offering

Business Wire

5 months ago

Arcus Biosciences Retains Rights to Casdatifan, a Potential Best-in-Class HIF-2a Inhibitor, and Announces Pricing of $150 Million Common Stock Offering

Business Wire

5 months ago

Arcus Biosciences, Inc. Announces Underwritten Offering of Common Stock

Business Wire

5 months ago

New Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney Cancer

Business Wire

5 months ago

Arcus Biosciences Announces New Employment Inducement Grants

Business Wire

5 months ago

Arcus Biosciences to Present New Data from Casdatifan, a HIF-2a Inhibitor, in an Oral Presentation at the 2025 ASCO GU Symposium

Argus Research

5 months ago

RCUS: What does Argus have to say about RCUS?

Business Wire

5 months ago

Arcus Biosciences Announces New Employment Inducement Grants

Argus Research

5 months ago

RCUS: What does Argus have to say about RCUS?

MT Newswires

5 months ago

Arcus Biosciences Appoints Richard Markus as Medical Chief

Arcus Biosciences Appoints Richard Markus, M.D., Ph.D. as Chief Medical Officer

Business Wire

5 months ago

Arcus Biosciences Appoints Richard Markus, M.D., Ph.D. as Chief Medical Officer

Argus Research

6 months ago

RCUS: Lowering target price to $15.00

Moderna (MRNA) Stock Jumps 11.7%: Will It Continue to Soar?

Zacks

6 months ago

Moderna (MRNA) Stock Jumps 11.7%: Will It Continue to Soar?

Business Wire

6 months ago

Arcus Biosciences Announces New Employment Inducement Grants

Argus Research

6 months ago

RCUS: What does Argus have to say about RCUS?

Shareholders in Arcus Biosciences (NYSE:RCUS) have lost 65%, as stock drops 9.9% this past week

Simply Wall St.

7 months ago

Shareholders in Arcus Biosciences (NYSE:RCUS) have lost 65%, as stock drops 9.9% this past week

Business Wire

7 months ago

Arcus Biosciences to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Argus Research

7 months ago

RCUS: Lowering target price to $17.00

Argus Research

7 months ago

RCUS: Raising target price to $18.00

Business Wire

7 months ago

Arcus Biosciences Announces New Employment Inducement Grants

Argus Research

7 months ago

RCUS: What does Argus have to say about RCUS?

Business Wire

7 months ago

Arcus Biosciences Announces New Employment Inducement Grants

Argus Research

7 months ago

RCUS: Raising target price to $17.00

Business Wire

8 months ago

Arcus Biosciences to Participate in Two Upcoming Investor Conferences

Argus Research

8 months ago

RCUS: Raising target price to $18.00

Business Wire

8 months ago

Arcus Biosciences Announces New Employment Inducement Grants

Analysts Have Made A Financial Statement On Arcus Biosciences, Inc.'s (NYSE:RCUS) Third-Quarter Report

Simply Wall St.

8 months ago

Analysts Have Made A Financial Statement On Arcus Biosciences, Inc.'s (NYSE:RCUS) Third-Quarter Report

Arcus Biosciences Inc (RCUS) Q3 2024 Earnings Call Highlights: Strong Cash Position and ...

GuruFocus.com

8 months ago

Arcus Biosciences Inc (RCUS) Q3 2024 Earnings Call Highlights: Strong Cash Position and ...

Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Tops Revenue Estimates

Zacks

8 months ago

Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Tops Revenue Estimates

Business Wire

8 months ago

Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update

Argus Research

8 months ago

RCUS: Lowering target price to $16.00

Business Wire

8 months ago

Arcus Biosciences Announces that Domvanalimab Plus Zimberelimab Improved Overall Survival in ARC-10, a Randomized Study in Patients with PD-L1-High Non-Small Cell Lung Cancer

What To Expect From Arcus Biosciences Inc (RCUS) Q3 2024 Earnings

GuruFocus.com

8 months ago

What To Expect From Arcus Biosciences Inc (RCUS) Q3 2024 Earnings

Regeneron (REGN) Tops Q3 Earnings and Revenue Estimates

Zacks

8 months ago

Regeneron (REGN) Tops Q3 Earnings and Revenue Estimates

Analysts Estimate Arcus Biosciences, Inc. (RCUS) to Report a Decline in Earnings: What to Look Out for

Zacks

8 months ago

Analysts Estimate Arcus Biosciences, Inc. (RCUS) to Report a Decline in Earnings: What to Look Out for

Business Wire

8 months ago

Arcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual Meeting

Exelixis (EXEL) Q3 Earnings and Revenues Beat Estimates

Zacks

8 months ago

Exelixis (EXEL) Q3 Earnings and Revenues Beat Estimates

Business Wire

8 months ago

Arcus Biosciences Announces New Employment Inducement Grants

MT Newswires

8 months ago

Arcus Biosciences Reports 'Encouraging' First Data for Casdatifan in Patients With Metastatic Kidney Cancer

Business Wire

8 months ago

First Clinical Data for Arcus Biosciences’ HIF-2a Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidney Cancer

Business Wire

8 months ago

Arcus Biosciences to Host Conference Call to Discuss Third-Quarter 2024 Financial Results and Pipeline Update

State Street Corp's Strategic Adjustment in Arcus Biosciences Holdings

GuruFocus.com

9 months ago

State Street Corp's Strategic Adjustment in Arcus Biosciences Holdings

Arcus Biosciences Inc (RCUS) Q2 2024 Earnings Call Highlights: Strategic Advancements Amid ...

GuruFocus.com

9 months ago

Arcus Biosciences Inc (RCUS) Q2 2024 Earnings Call Highlights: Strategic Advancements Amid ...

Business Wire

9 months ago

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc.'s (NYSE:RCUS) Intrinsic Value Is Potentially 30% Above Its Share Price

Simply Wall St.

9 months ago

Arcus Biosciences, Inc.'s (NYSE:RCUS) Intrinsic Value Is Potentially 30% Above Its Share Price

Business Wire

9 months ago

Arcus Biosciences to Present First Clinical Data from ARC-20 Study at the 2024 EORTC-NCI-AACR Symposium

Argus Research

9 months ago

RCUS: Raising target price to $18.00

MT Newswires

9 months ago

Wells Fargo Initiates Arcus Biosciences at Overweight With $29 Price Target

MT Newswires

9 months ago

Arcus Biosciences, AstraZeneca Collaborate on Developing Carcinoma Treatment

Business Wire

9 months ago

Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in Renal Cell Carcinoma

Business Wire

9 months ago

Arcus Biosciences Announces New Employment Inducement Grants

Business Wire

10 months ago

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences obtains loan facility with Hercules Capital worth $250m

Pharmaceutical Technology

10 months ago

Arcus Biosciences obtains loan facility with Hercules Capital worth $250m

Argus Research

10 months ago

RCUS: Lowering target price to $18.00

MT Newswires

10 months ago

Arcus Biosciences Gets Up to $250 Million Term Loan Facility From Hercules Capital

Business Wire

10 months ago

Arcus Biosciences Secures Up to $250 Million Term Loan Facility from Hercules Capital

Business Wire

10 months ago

Arcus Biosciences Announces New Employment Inducement Grants

Share on Social Networks: